We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

4927:TSEPola Orbis Holdings Inc. Analysis

Data as of 2026-05-25 - not real-time

NT$61.90

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Apex International Co., Ltd. is trading at the upper end of its 52‑week range, hugging the recent resistance of 61.9 TWD while staying above the 20‑day SMA (≈54) and the 50‑day SMA (≈49), a classic bullish alignment. Momentum indicators remain supportive – the RSI sits at 65, and the MACD line is above its signal, generating a bullish histogram. However, volume is trending down, and the stock’s 30‑day volatility is unusually high at over 84%, suggesting price swings could accelerate. Fundamentally, the company is distressed: revenues are contracting, margins are deeply negative, and the balance sheet is leveraged with a debt‑to‑equity ratio above 190%. Cash reserves cover only a fraction of total debt, and both operating and free cash flow are negative. Yet, the forward PE of 7.7 is dramatically below the industry average of 39.5, and the forward EPS projection turns positive, indicating a potential valuation gap if the turnaround materialises. Market sentiment is extremely greedy (Fear‑Greed Index 91.8), which may be inflating the price despite the underlying financial weaknesses.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish technical alignment but price near resistance
  • Decreasing volume indicating possible short‑term pullback
  • High short‑term volatility could trigger rapid moves

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward earnings estimate turns positive while valuation remains cheap
  • Bullish MACD and RSI still supportive of upside
  • Potential upside if the company stabilises cash flow and reduces leverage

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Significant debt burden and negative cash flows pose structural risk
  • Sector cyclicality may limit sustained growth
  • Valuation upside limited unless a credible turnaround plan is executed

Key Metrics & Analysis

Financial Health

Revenue Growth-12.00%
Profit Margin-22.65%
P/E Ratio7.7
ROE-44.04%
ROA-6.87%
Debt/Equity191.15
P/B Ratio2.8
Op. Cash FlowNT$-1228942976
Free Cash FlowNT$-417409376
Industry P/E39.5

Technical Analysis

TrendBullish
RSI65.4
SupportNT$45.05
ResistanceNT$61.90
MA 20NT$54.04
MA 50NT$49.22
MA 200NT$33.79
MACDBullish
VolumeDecreasing
Fear & Greed Index91.8

Valuation

GradeUndervalued
TypeValue

Risk Assessment

Beta1.01
Volatility84.19%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.